TOP STANDARD CORP(08510.HK)将每股配售价调整为0.112元 今早复牌
TOP STANDARD CORP(08510.HK)公布,公司与配售代理订立有关配售事项的补充协议以修订配售价,配售价由每股配售股份0.11元调整为每股配售股份0.112元,较上周五(14日)收市价每股0.096元溢价约16.67%。
待配售事项完成後,假设所有配售股份获悉数配售,预期配售事项之所得款项净额将约为1,718.24万元。
应公司要求,股份已於自昨日(17日)起在联交所暂停买卖,以待刊发此公告。公司已向联交所申请於今天(18日)上午9时正起恢复股份在联交所买卖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.